Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

OBJECTIVES: With the poorest 5‐year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Immunology
Main Authors: Van Audenaerde, Jonas RM, Marcq, Elly, von Scheidt, Bianca, Davey, Ashleigh S, Oliver, Amanda J, De Waele, Jorrit, Quatannens, Delphine, Van Loenhout, Jinthe, Pauwels, Patrick, Roeyen, Geert, Lardon, Filip, Slaney, Clare Y, Peeters, Marc, Kershaw, Michael H, Darcy, Phillip K, Smits, Evelien LJM
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7428816/
https://ncbi.nlm.nih.gov/pubmed/32821382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados